Earn rewards for your opinion on lab products.
Get exclusive insights into life science trends.
Stay up to date on research news.
11.7T MR spectroscopy quantifies brain glucose metabolism
May 17, 2022 -- French researchers have developed a new MR (magnetic resonance) spectroscopy approach to study brain glucose metabolism, a process significantly involved in Alzheimer's disease. They presented their work in an animal study at the annual meeting of the International Society for Magnetic Resonance in Medicine. Read More
Sample management, characterization is a growing challenge in CGT
May 16, 2022 -- From academic research centers to small biotechs to large pharmaceutical companies, the numbers of biosamples and measurements are growing exponentially in the field of cell and gene therapy (CGT). Andrea O'Hara and David Lewandowski of Azenta Life Sciences, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting about the challenge of sample management and characterization. Read More
Autologous cell therapy has its limitations, risks
May 16, 2022 -- Cell-based therapies generated using a patient's own cells, called autologous cell therapy, have their own inherent risks and limitations, contends Roman Vincent, senior global director of strategic marketing at MaxCyte. Vincent spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting in San Francisco. Read More
What's needed for cell and gene therapies to become the new standard of care?
May 13, 2022 -- Cell and gene therapies (CGTs) have the potential to be the new standard of care. Delara Motlagh, PhD, general manager at Terumo Blood and Cell Technologies, told ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting that increasing access to CGTs is critical to making that a reality. Read More
Automation, standardization hold potential for overcoming CGT manufacturing challenges
May 12, 2022 -- Challenges in cell and gene therapy (CGT) manufacturing can be overcome by fully automating and standardizing the process, contends David Smith, vice president of technical operations at Ori Biotech. Smith spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting about Ori Biotech's new digital platform that closes, automates, and standardizes CGT manufacturing. Read More
CGT ecosystem is only way to accelerate development for more patients: Autolomous COO
May 12, 2022 -- Digital solutions provider Autolomous specializes in building solutions for the cell and gene therapy (CGT) industry with an emphasis on collaborative partnerships with suppliers across the value chain. Kwok Pang, the company’s chief operating officer (COO), spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting in San Francisco. Read More
Galipeau to replace Levine as ISCT president
May 11, 2022 -- Dr. Jacques Galipeau, associate dean for therapeutics development at the University of Wisconsin-Madison, is set to replace Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, as the next president (2022-2024) of the International Society for Cell & Gene Therapy (ISCT). Read More
ISCT22 co-chair recounts how far CGT industry has come
May 11, 2022 -- Advancements in the field of cell and gene therapies (CGTs) have made them a therapeutic reality, according to Bambi Grilley, director of clinical research and early product development at Baylor College of Medicine, and co-chair of the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting. Grilley spoke with ScienceBoard.net at the meeting about the evolution of the CGT industry which is driving clinical translation of CGTs that are benefitting patients. Read More
ISCT22: Scale up of cell therapy manufacturing is a significant, but addressable challenge
May 10, 2022 -- The cell therapy industry is facing a significant but addressable challenge when it comes to scaling up manufacturing, according to Bob Newman, PhD, chief scientific officer at FujiFilm Irvine Scientific. ScienceBoard.net spoke with Neman during the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting. Read More
ISCT22: RoosterBio, ShiftBio partner to harness the power of MSCs, exosomes
May 10, 2022 -- RoosterBio, a supplier of human mesenchymal stem/stromal cells (MSCs), recently announced a strategic partnership with ShiftBio, a South Korean company that specializes in exosome technology. Tim Kelly, PhD, CEO of RoosterBio, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. Read More
ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation
May 9, 2022 -- Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic cell creation by enabling simultaneous silencing of multiple gene targets while overcoming the challenges faced by existing gene editing approaches. Kili spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. Read More
ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
May 9, 2022 -- Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes to get them to patients, according to Patrick Hanley, PhD, chief and director of the pediatric medical center’s Cellular Therapy Program. Hanley spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. Read More
ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
May 9, 2022 -- Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. However, several factors make CGTs complex, expensive, and difficult to bring to market, including small/personalized batch production and the fact that everything must be conducted in a very sterile environment. Read More
ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
May 9, 2022 -- Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco about how BroadOak’s medium- to long-term investment strategy sees “great science” happening in the sector that’s improving productivity and advancing cell and gene therapies (CGTs), biologics, and other modalities. Read More
ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
May 6, 2022 -- Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about regenerative medicine and orthopedics. Read More
Science In Brief
Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
May 4 - June 7
San Francisco, California United States
35th International Symposium on Preparative and Process Chromatography (PREP 2022)
May 15-18
Baltimore, Maryland United States
May 15-18
Baltimore, Maryland United States
American Society of Cell & Gene Therapy Annual Meeting
May 16-19
Washington, District of Columbia United States
May 16-19
Washington, District of Columbia United States
Interphex 2022 Conference
May 24-26
New York, New York United States
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
June 5-9
Minneapolis, Minnesota United States
Connect
Latest Tweets